Applications of (R)-4-Boc-Piperazine-3-Carboxylic Acid in Industrial Manufacturing

As a specialized manufacturer of (R)-4-Boc-Piperazine-3-Carboxylic Acid, we enable high-purity intermediate supply for tightly regulated downstream processes. Our quality assurance and controlled synthesis support pharmaceutical, peptide, and research entities requiring this compound for advanced synthesis steps within strictly defined operational scopes.

1. Chiral Intermediate in Small-Molecule Drug Synthesis

The compound serves as a vital chiral building block in assembling several advanced pharmaceutical actives, particularly for piperazine-based drug entities. Downstream customers use this acid in coupling and condensation steps requiring controlled stereochemistry, such as in the production of antihistamines and neurological drugs. Integration takes place after initial backbone assembly, often preceding deprotection and final purification. Usage ratios adapt to the target molecule and coupling efficiency, with strict control maintained under cGMP conditions to prevent residuals or cross-contamination and ensure the isolated intermediates meet pharma-grade purity.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients
• United States Pharmacopeia (USP) monograph compatibility (where applicable)
• European Pharmacopoeia reference standards
• FDA 21 CFR Part 210/211 for finished pharmaceuticals

Typical usage ratio

• Used at 0.6–1.2 molar equivalents relative to complementary drug precursor; adjustment depends on required chemoselectivity and excess for complete coupling

Downstream process integration

• Incorporated during either amidation or N-acylation step after scaffold formation; downstream deprotection and hydrogenation follow

Final product types

• API intermediates for CNS active compounds (e.g., piperazine-containing antipsychotics, antiemetic formulations)
• Industrial-scale advanced intermediates for medicinal chemistry projects

2. Peptide Modification in Pharmaceutical Research

In peptide drug development, the acid provides a protected chiral nitrogen functionality, enabling the introduction of rigidified moieties at specific positions on a peptide chain. Researchers incorporate it during solid-phase synthesis for selective side chain elaboration, allowing downstream deprotection and conjugation. The precise loading depends on resin functionalization and the complexity of the target sequence. All steps require compliance with high-purity and traceability demands for laboratory and eventual pilot-scale peptide drug candidates.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• European Pharmacopoeia standards for peptide synthesis
• ISO 9001:2015 for laboratory and research-use only reagents
• USP <1047> General Chapter: Peptide Synthesis

Typical usage ratio

• Loaded at 0.8–1.0 molar equivalents per target modification site on peptide; refined based on coupling efficiency and sequence sterics

Downstream process integration

• Added during mid-sequence stepwise peptide elongation on solid support; deprotected and elaborated in post-synthesis modifications

Final product types

• Sequence-defined polypeptides with site-specific rigidification
• Peptide research tools and drug leads containing stereodefined piperazine units

3. Fine Chemical Intermediate in Custom Synthesis

The acid is frequently sourced as a ready-protected intermediate for fine chemical companies manufacturing specialty ligands, linkers, or custom molecular fragments. Downstream chemists use it in stepwise transformations where protection from side reactions is essential, introducing it at a stage that allows easy removal of Boc before final couplings or cyclization. Usage rates adjust based on batch scale and anticipated yield for each project, and traceability supports later regulatory dossiers for customer transfer.

Industry compliance standards

• ISO 9001:2015 certified process protocols
• REACH compliance for handling and transport, EU markets
• Internal specifications for fine chemical QC (NMR, HPLC purity, chiral integrity)
• GMP documentation on request for regulated synthesis

Typical usage ratio

• 1.0–1.1 molar equivalents per batch, depending on step selectivity and target synthesis design; extra may be used to secure full conversion

Downstream process integration

• Employed after initial backbone formation as a coupling partner or protected moiety, followed by further derivatization or Boc deprotection ahead of target fragment assembly

Final product types

• Specialty ligands for catalysis research
• Custom fine chemical fragments incorporated in new molecule development

4. Chiral Auxiliary for Biotech Catalysis Screening

Biotech process development relies on the acid as a molecular auxiliary in electrophilic catalysis exploration. Research groups add it to chiral pools for screening enantioselective biocatalysts, leveraging its distinct protected group to monitor bioconversion and facilitate downstream product isolation. The added amount reflects the assay scale and target conversion tracking method, with careful recording to align with audit trails in regulated discovery.

Industry compliance standards

• OECD Principles of Good Laboratory Practice for biotech process screening
• ISO/IEC 17025 for R&D analytical methods
• Custom internal SOPs for biocatalytic research supply
• ISO 9001:2015 for quality management of R&D materials

Typical usage ratio

• 0.5–1.0 molar equivalents per catalyst screening batch; scaled for microtiter plate or small batch fermentation, set by substrate conversion rates

Downstream process integration

• Introduced during biocatalyst exposure assays as a chirally pure electrophilic substrate; assists in identifying selective enzyme action before Boc deprotection or further downstream conversion

Final product types

• Chiral screening libraries for enzyme selectivity mapping
• Biocatalytic research intermediates for further transformation